We are live on
!
Find out more
ABG
Ally Bridge Group Portfolio holdings
AUM
$113M
1-Year Est. Return
245.92%
This Fund
S&P 500
This Quarter
Est. Return
+16.04%
1 Year Est. Return
+245.92%
3 Year Est. Return
+826.04%
5 Year Est. Return
+770.7%
10 Year Est. Return
–
AUM
$113M
AUM Growth
-$10.7M
(-8.7%)
Cap. Flow
-$30.4M
Cap. Flow
% of AUM
-26.9%
Top 10 Holdings %
Top 10 Hldgs %
70.48%
Holding
39
New
12
Increased
2
Reduced
9
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
TRAX
First Tracks Biotherapeutics
TRAX
|
+$5.31M |
| 2 |
Assembly Biosciences
ASMB
|
+$3.81M |
| 3 |
Axsome Therapeutics
AXSM
|
+$3.58M |
| 4 |
Minerva Neurosciences
NERV
|
+$2.82M |
| 5 |
Kura Oncology
KURA
|
+$2.74M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Praxis Precision Medicines
PRAX
|
+$10.6M |
| 2 |
SLNO
Soleno Therapeutics
SLNO
|
+$6.7M |
| 3 |
CMPS
Compass Pathways
CMPS
|
+$5.78M |
| 4 |
Tarsus Pharmaceuticals
TARS
|
+$5.67M |
| 5 |
Ovid Therapeutics
OVID
|
+$5.66M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 68.63% |
| 2 | Miscellaneous | 31.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
DFTX
1
CALL
Definium Therapeutics
DFTX
$5.11B
| $18.8M | 16.64% |
+400,000
| New | +$9.88M |
|
|
ABVX
2
CALL
Abivax
ABVX
$9.95B
| $16.7M | 14.73% |
+125,000
| New | +$14.1M |
|
|
3
Minerva Neurosciences
NERV
$224M
| $12.1M | 10.68% |
2,175,802
+520,302
| +31% | +$2.82M |
|
4
ProMIS Neurosciences
PMN
$116M
| $8.16M | 7.22% |
620,319
+206,100
| +50% | +$2.24M |
|
|
TRAX
5
First Tracks Biotherapeutics
TRAX
$1.52B
| $5.72M | 5.06% |
+284,287
| New | +$5.31M |
|
|
6
Axsome Therapeutics
AXSM
$10.9B
| $4.04M | 3.57% |
+16,493
| New | +$3.58M |
|
|
7
Assembly Biosciences
ASMB
$736M
| $3.85M | 3.4% |
+140,000
| New | +$3.81M |
|
|
WHWK
8
Whitehawk Therapeutics
WHWK
$264M
| $3.75M | 3.31% |
817,939
| – | – |
|
9
Edgewise Therapeutics
EWTX
$4.56B
| $3.38M | 2.99% |
83,300
-77,700
| -48% | -$2.68M |
|
|
CLYM
10
Climb Bio
CLYM
$838M
| $3.25M | 2.87% |
+249,172
| New | +$2.57M |
|
|
11
Kura Oncology
KURA
$1.17B
| $3.18M | 2.81% |
+290,000
| New | +$2.74M |
|
12
CytomX Therapeutics
CTMX
$802M
| $2.91M | 2.57% |
775,000
-125,000
| -14% | -$477K |
|
13
Avalo Therapeutics
AVTX
$1.02B
| $2.77M | 2.45% |
+150,000
| New | +$2.37M |
|
14
Palisade Bio
PALI
$356M
| $2.57M | 2.27% |
+1,229,000
| New | +$2.42M |
|
15
Solid Biosciences
SLDB
$1.12B
| $2.56M | 2.26% |
255,959
-511,015
| -67% | -$3.87M |
|
16
AN2 Therapeutics
ANTX
$225M
| $2.55M | 2.25% |
526,315
| – | – |
|
17
UroGen Pharma
URGN
$2.19B
| $2.55M | 2.25% |
69,183
-132,941
| -66% | -$3.6M |
|
18
Perspective Therapeutics
CATX
$356M
| $2.54M | 2.24% |
743,958
-182,599
| -20% | -$690K |
|
19
IDEAYA Biosciences
IDYA
$3.86B
| $2.52M | 2.22% |
+67,500
| New | +$2.07M |
|
|
IVA
20
Inventiva
IVA
$1.14B
| $2.4M | 2.12% |
634,800
-110,500
| -15% | -$531K |
|
|
ALMS
21
Alumis Inc
ALMS
$1.47B
| $2.15M | 1.9% |
76,459
-90,500
| -54% | -$2.11M |
|
|
22
Ovid Therapeutics
OVID
$543M
| $1.68M | 1.49% |
624,561
-2,193,898
| -78% | -$5.66M |
|
|
EPRX
23
Eupraxia Pharmaceuticals
EPRX
$496M
| $1.67M | 1.47% |
252,175
-408,200
| -62% | -$2.81M |
|
24
iBio
IBIO
$83.6M
| $683K | 0.6% |
+390,147
| New | +$698K |
|
25
Traws Pharma
TRAW
$8.33M
| $663K | 0.59% |
+786,236
| New | +$1.08M |
|
Similar funds
IA
CPA
MBC
OCM
AWA
TWS
OFP
IIM
Ally Bridge Group's Q2 2026 Portfolio in Review
As of Q2 2026, Ally Bridge Group held 39 positions worth $113M, down 8.7% from $124M the previous quarter. Its ten largest holdings account for 70% of the portfolio.
Ally Bridge Group withdrew a net $30.4M in Q2 2026, closing 14 positions and reducing 9 holdings. Its most notable exit was Praxis Precision Medicines, an estimated $10.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 81% a quarter earlier, followed by Miscellaneous.
Against the trend, Ally Bridge Group opened a new position in First Tracks Biotherapeutics worth $5.72M.
- Ally Bridge Group's largest Q2 2026 buy was First Tracks Biotherapeutics: 284,287 shares worth $5.72M.
- Ally Bridge Group added most to Minerva Neurosciences in Q2 2026, an estimated $2.82M increase.
- Ally Bridge Group's biggest Q2 2026 reduction was Ovid Therapeutics, cutting an estimated $5.66M.
- Ally Bridge Group fully exited Praxis Precision Medicines in Q2 2026, selling an estimated $10.6M.
- Ally Bridge Group's ten largest holdings make up 70% of its $113M portfolio in Q2 2026.
- Ally Bridge Group opened 12 new positions and closed 14 in Q2 2026.
- Ally Bridge Group's portfolio value fell 8.7% quarter-over-quarter to $113M.
Based on Ally Bridge Group's 13F filing for Q2 2026, filed 14 Aug 2026.